Table 4.

Testing technologies and potential markers for monitoring MRD in AML

Testing technologiesPotential markers
MFCCD2CD34
CD4CD45
CD7CD56
CD13CD123
CD15CD117
CD19HLA-DR
CD33
NGSNPM1
RUNX1
FLT3-ITD
IDH1/IDH2
RT-qPCRCBFB/MYH11
FLT3-ITD
IDH1/IDH2
NPM1
RUNX1/RUNX1T1
t(10;11) – KMT2A-MLLT10
t(11;19) – KMT2A-ELL or KMT2A-MLLT1
t(6;11) – KMT2A-MLLT4
t(9;11) – KMT2A-MLLT3
WT1
  • MLL/MLLT3, mixed lineage leukemia.